Reading CI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CI free→Reading CI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CI free→NYSEHealth CareHealthcare PlansSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality is mixed, and the sector backdrop is a headwind, indicating challenges in the broader market. Peer multiples imply a price about 48% above where it trades (it looks cheap on this basis); the read is cheap, quality intact. Key factors to watch include guidance changes and sector trends, as these could significantly impact the stock's performance. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $298.00. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $298 CI trades at 10× p/e, below its 19× p/e peer median. Our $575 fair value sits above the price; low confidence. Analysts: $302–$400. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 48% below a flat-multiple fair value, below our forecast of about 12%. This describes what's priced in, not a forecast of the move.
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.42x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
17 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $7.56 → $7.57 (+0.1% / 30d). 4 raised, 4 cut, 21 covering analysts.
0 upgrades, 2 downgrades / 30d, 3 maintained. 83% of analysts rate Buy.
5 PT revisions / 30d. Avg target 18.6% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$126.
How much price usually moves either way.
On a bad day, this stock has moved -$265.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,655.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Progress on this target shows Cigna's ability to grow its healthcare segment. It is crucial for overall growth.
Confirms:Cigna Healthcare's income target is better in the Q2 earnings report.
Disproves:Cigna Healthcare's income target stayed the same or got worse in Q2.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CI yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Regulation FD Disclosure. 2026 Outlook Affirmation The Cigna Group (or “our”) officials expect to participate in meetings with investors and analysts over the next several weeks. During these meetings, The Cigna Group officials expect to reaffirm projected full year 2026 consolidated adjusted income from operations on a per share basis of at least $30.35 per share. The Cigna Group previously discussed its full year 2026 outlook in its press release dated April 30, 2026, and during the related…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$302.00 – $400.00 (median $338.50) · 12 analysts · as of 2026-06-08
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Services.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CI Cigna | Above typical Show detailsSector percentile: 88 of 100 | inexpensive | moderate |
CVS CVS Health | Typical Show detailsSector percentile: 60 of 100 | fair | moderate |
DGX Quest Diagnostics | Typical Show detailsSector percentile: 68 of 100 | full | moderate |
LH Labcorp | Above typical Show detailsSector percentile: 75 of 100 | fair | moderate |
DVA DaVita | Above typical Show detailsSector percentile: 83 of 100 | inexpensive | moderate |
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Cigna aims to increase its adjusted income from operations, reaffirming a target of at least $30.35 per share for 2026.
Cigna aims to achieve a pre-tax adjusted income from operations of at least $4.5 billion for Cigna Healthcare in 2026.
Cigna aims to achieve an adjusted revenue of approximately $280 billion for the full year 2026.
Why it matters: This figure is a key target for Cigna's growth. Meeting it shows solid performance.
Confirms:Adjusted income from operations for 2026 reaches at least $30.35 per share.
Disproves:Adjusted income from operations falls below $30.35 per share.
Results of Operations and Financial Condition. On April 30, 2026, The Cigna Group issued a press release announcing results for the three months ended March 31, 2026. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities A…
CEO — Mr. David M. Cordani and Mr. Brian C. Evanko: David M. Cordani is retiring as CEO, and Brian C. Evanko is being promoted to succeed him.
Regulation FD Disclosure. The Company is reaffirming projected full year 2026 consolidated adjusted income from operations of at least $30.25 per share. The Company is also reaffirming 2026 Evernorth pre-tax adjusted income from operations of at least $6.9 billion, and Cigna Healthcare pre-tax adjusted income from operations of at least $4.5 billion. The Cigna Group previously discussed its full year 2026 outlook in its press release dated February 5, 2026, and during the related investor con…
Regulation FD Disclosure. 2026 Outlook Affirmation The Cigna Group (or “our”) officials expect to participate in meetings with investors and analysts over the next several weeks. During these meetings, The Cigna Group officials expect to reaffirm projected full year 2026 consolidated adjusted income from operations on a per share basis of at least $30.25 per share. The Cigna Group previously discussed its full year 2026 outlook in its press release dated February 5, 2026, and during the relat…